OCTO-TELEMATICS
20.5.2020 10:03:03 CEST | Business Wire | Press release
OCTO, a market leader in providing smart solutions by transforming its IoT Big Data set into actionable intelligence for a sustainable connected life, is pleased to announce the launch of two products designed to support companies' return back to business as they transition to the “new normal” following the COVID-19 pandemic. These innovative solutions encourage safe self-distancing and the robust sanitization of vehicles. At the forefront of the design principals, OCTO developed products are easy to implement and manage, while being highly effective. Protecting the workforce and their livelihoods, as well as protecting customers and fostering higher levels of trust.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200520005174/en/
OCTO AroundMe is based on OCTO’s proven SmartTag technology that utilises the latest Bluetooth standards, OCTO’s IoT cloud platform and is compatible with both iOS and Android smartphones. OCTO AroundMe allows for easy management of social distancing in both public and private spaces, such as stores or office buildings. The pocket-sized SmartTag carried by visitors or employees continuously monitor an individual’s proximity, in this case and under government guidelines this has been automatically set to two metres. Should two people inadvertently have a distance less than two meters apart, an audible alert would remind them to keep a safe distance. The event would also be captured anonymously and stored on the cloud for reporting and analysis, to better understanding and mitigate future risk. To further mitigate any risks, using OCTO AroundMe within closed environments also allows for easy and effective crowd control and building capacity management as it stores all entry and exit information.
OCTO PurePlace uses nano technology originally developed by the National Aeronautics and Space Administration (NASA), that eliminates viruses, bacteria, fungi as well as odours and volatile organic compounds in the air and on surfaces via a purifier. It is a non-invasive solution, safe to people and all materials commonly found within vehicle interiors. As well as the purifier device, the complete OCTO PurePlace solution consists of an onboard telematics device (OCTO SmartDiag or OCTO SuperEasy) and an application compatible with iOS and Android smartphones.
OCTO PurePlace has been designed to protect drivers and passengers across corporate fleets, rental fleets, carsharing and taxi operators. It allows for the easy and effective sanitization of vehicles during a trip with intermittent self-activation and the end of each journey with a full sanitization cycle. To ensure absolute safety and confidence, before entering the vehicle, both the driver and passenger can be notified regarding the state of sanitization via a smartphone app. For the operator and the safe management of the fleet, if the sanitization is not complete, the vehicle may be temporarily suspended from public use.
ABOUT OCTO
Founded in 2002, OCTO is a leading provider of telematic services and advanced data analytics for the insurance sector, and increasingly one of the leading companies offering solutions for Fleet Telematics and Smart Mobility. With OCTO’s unique propositions already established in the field of Insurtech and Smart Mobility, OCTO continues to expand in new sectors and international markets. In the context of an increasingly connected world, OCTO’s advanced analytics and its set of IoT Big Data, generates actionable analytics giving life to a new era of Smart Telematics. Today it has over 6 million connected users and the largest database of vehicle telematics data in the world, with over 267 billion miles of driving data collected and 473,000 claims and insurance events analysed. It also manages over 400,000 vehicle rentals per month.
OCTO does not guarantee, represent or warrant that the use of a photocatalytic oxidation purifier used in the OCTO PurePlace will prevent a vehicle’s occupant(s) from contracting any type of bacteria or virus-based illness, including, but not limited to, the common cold, coronavirus or influenza.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005174/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
